Skip to main content

Table 2 Clinicopathological Features in Each Molecular Group

From: Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas

  Conventional EBV-positive MSI-high
(n = 429) (n = 32) (n = 53)
Sex
 Male 290 (68%) 24 (75%) 33 (62%)
 Female 139 (32%) 8 (25%) 20 (38%)
Age, median (years, range) 65 (27–88) 63 (45–88) 64 (34–82)
Tumor site   *aP < 0.001  
 Lower 1/3 287 (67%) 4 (13%) 41 (77%)
 Middle 1/3 85 (20%) 11 (34%) 7 (13%)
 Upper 1/3 57 (13%) 17 (53%) 5 (9%)
Histologic type    *bP = 0.006
 Tubular adenocarcinoma 343 (80%) 29 (91%) 43 (81%)
 Poorly cohesive 76 (18%) 2 (6%) 5 (9%)
 Mucinous carcinoma 5 (1%) 0 4 (8%)
 Undifferentiated 5 (1%) 1 (3%) 1 (2%)
Lauren   *aP = 0.029  
 Intestinal 246 (57%) 12 (38%) 28 (53%)
 Diffuse 183 (43%) 20 (63%) 25 (47%)
Lymphatic invasion    *bP < 0.001
 Present 182 (42%) 11 (34%) 37 (70%)
Depth of invasion (pT)    *bP = 0.031
 pT1 (mucosa, submucosa) 229 (53%) 17 (53%) 16 (30%)
 pT2 (muscularis proper) 37 (9%) 3 (9%) 6 (11%)
 pT3 (subserosa) 79 (18%) 2 (6%) 16 (30%)
 pT4 (serosa or beyond) 84 (20%) 10 (31%) 15 (28%)
Lymph node metastasis
 Present 177 (41%) 10 (31%) 28 (53%)
Tumor stage (pTNM)    *bP = 0.028
 Stage I 238 (55%) 20 (63%) 19 (36%)
 Stage II 64 (15%) 3 (9%) 14 (26%)
 Stage III 105 (24%) 7 (22%) 18 (34%)
 Stage IV 22 (5%) 2 (6%) 2 (4%)
  1. EBV Epstein-Barr virus, MSI Microsatellite instability; Conventional, EBV-negative and non-MSI-high
  2. P values with statistically significant differences (< 0.05) are marked with an asterisk (*)
  3. aP value between EBV-positive gastric carcinomas and conventional gastric carcinomas
  4. bP value between MSI-high gastric carcinomas and conventional gastric carcinomas